Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Mereo BioPharma Group plcNASDAQ: MREO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $304.49K rose 12.8% year over year, behind the +15.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 48.6% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Depreciation & amortization amounted to 229.8% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +12.8% toward the trailing-twelve-month pace of +15.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.15M USD
- Year-over-year change
- +5.6%
- 4-year CAGR
- +7.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15M | +5.6% |
| FY2024 | 2024-12-31 | 1.09M | +2.5% |
| FY2023 | 2023-12-31 | 1.06M | +18.5% |
| FY2022 | 2022-12-31 | 895.5K | +3.4% |
| FY2021 | 2021-12-31 | 866.47K | — |
Depreciation & Amortization vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.6% is the 3rd highest of 10, against a peer median of +3.1%.
- Depreciation & amortization amounts to 249.7% of revenue for MREO, versus a peer median of 42.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1B USD | +66925.2% | +52.5% | — | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| FY2025 | A$2.13M AUD | +6.0% | +5.1% | 42.3% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M USD | +4.8% | +22.0% | — |
| LTM Mar 2026 | $1.65M USD | -13.9% | +19.6% | — | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
| LTM Mar 2026 | $1.25M USD | +15.6% | +8.7% | 249.7% | |
| LTM Mar 2026 | $749K USD | -23.9% | +2.8% | — | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K USD | +19.3% | -0.6% | — |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
| Peer median (excluding MREO) | — | +3.1% | +3.7% | 42.9% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.21M | 0 | 10M | 0 | 500K |
| Cost of Revenue | 24.17M | (257.44K) | 2.57M | 1.09M | 133K |
| Gross Profit | 25.04M | 257.44K | 7.43M | (1.09M) | 367K |
| Gross Margin | 50.9% | — | 74.3% | — | 73.4% |
| Research & Development | 31.8M | 30.75M | 17.42M | 20.93M | 17.77M |
| Selling, General & Admin | 21.5M | 23.18M | 18.42M | 26.43M | 23.01M |
| Operating Expenses | 53.3M | 53.92M | 35.84M | 47.36M | 38.62M |
| Depreciation & Amortization | 866.47K | 895.5K | 1.06M | 1.09M | 1.15M |
| EBITDA | 25.49M | (39.98M) | (26.06M) | (40.8M) | (40.47M) |
| EBITDA Margin | 51.8% | — | -260.6% | — | -8094.8% |
| Operating Income | (28.26M) | (53.67M) | (28.42M) | (47.36M) | (38.26M) |
| Operating Margin | -57.4% | — | -284.2% | — | -7651.4% |
| Interest Income | 1.38K | 696K | 2.13M | 3.04M | 2.17M |
| Interest Expense | 5.22M | 3.36M | 2.88M | 1.37M | 255K |
| Other Income / Expenses | 47.48M | 9.21M | (1.58M) | 4.11M | (3.62M) |
| Income Before Tax | 19.22M | (44.46M) | (30M) | (43.25M) | (41.88M) |
| Pre-Tax Margin | 39.1% | — | -300.0% | — | -8375.6% |
| Income Tax Expense | 2.05M | (2.34M) | (532K) | 0 | 0 |
| Net Income | 17.17M | (42.12M) | (29.47M) | (43.25M) | (41.88M) |
| Net Margin | 34.9% | — | -294.7% | — | -8375.6% |
| EPS (Basic) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| EPS (Diluted) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| Weighted Avg Shares | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
| Weighted Avg Shares (Diluted) | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.